Sunesis Pharmaceuticals is paring 35 workers, or 25 percent of its staff, in an effort to pare out $10 million in costs. Research and general administrative areas will be cut the most as the developer concentrates on advancing its lead therapy, SNS-595 for leukemia and ovarian cancer. Sunesis had $65.2 million in cash on hand at the end of June.
- see the announcement on the cuts